A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391

NCT05634447 | Completed Phase 1

• 1 other identifier: A52_10BE2220
• Study Type: interventional
• Target: 69
• Locations: 1 country
• Sites: 1

Brief Summary

A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-391

Conditions

Dyslipidemias

Keywords

CKD-391

Outcome Measures

Primary Outcomes (2)

• Primary Outcome Measure

  AUCt of CKD-391: Area under the concentration-time curve time zero to time

  Pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hours

• Primary Outcome Measure

  Cmax of CKD-391: Maximum plasma concentration of the drug

  Pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hours

Study Arms (2)

Sequence 1

EXPERIMENTAL

* Period 1: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition * Period 2: CKD-391 - A single oral dose of 1 tablet under fasting condition * Period 3: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition * Period 4: CKD-391 - A single oral dose of 1 tablet under fasting condition

Drug: Drug: CKD-391, QD, PO

Sequence 2

EXPERIMENTAL

* Period 1: CKD-391 - A single oral dose of 1 tablet under fasting condition * Period 2: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition * Period 3: CKD-391 - A single oral dose of 1 tablet under fasting condition * Period 4: CKD-331, D337 - A single oral dose of 2 tablets under fasting condition

Drug: Drug: CKD-391, QD, PO

Interventions

Drug: CKD-391, QD, PO DRUG

Drug: CKD-331, D337 QD, PO

Sequence 1; Sequence 2

Eligibility Criteria

• Age: 19 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult aged between 19 to 55 at screening
• Weight ≥ 50kg(man) or 45kg(woman), with calculated body mass index (BMI) of 18 to 30kg/m2
• Those who have no clinically significant congenital or chronic diseases and have no abnormal symptoms of findings
• Those who are deemed suitable for clinical trials based on laboratory (hematology, blood chemistry, serology, urinalysis, urine drug test) and 12-lead ECG results at screening
• Those who agree to contraception from the first IP dosing day till 14 days after the last dosing day and decide not to provide sperm during the participation of clinical trial
• Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial

You may not qualify if:

• Those who have used drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the first dosing date, or who have used drugs that may interfere with this study within 10 days before the first dosing day
• Those who exceed an alcohol, caffeine and cigarette consumption (caffeine\> 5 cups/day, alcohol\> 21 glasses/week(man), 14 glasses/week(woman), smoking\> 20 cigarettes/day) and not able to stop on smoking, caffeine and alcohol
• Those who received investigational products or participated in bioequivalence test within 6 months before the first administration of clinical trial drugs
• Those who donated whole blood within 8 weeks before the first date of administration and donated ingredients within 2 weeks or received blood transfusion in 4 weeks
• Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery
• Patients with the following diseases
• Patients with active liver disease or with elevated amino transferase levels with unknown cause increased by more than 3 times the normal upper limit
• Patients with severe liver failure or biliary obstruction and bile congestion
• Patients with muscular disease, rhabdomyolysis, or persons with a past history
• Patients with hypothyroidism, patients with genetic muscle disease or their family history, and patients with history of muscle disability due to drugs
• Patients with renal impairment or a history of in and patients with severe renal dysfunction
• Patients with a history of muscle toxicity to other statin drugs or fibrate drugs
• Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• Those who have hypersensitivity to the main constituents or components of the investigational drug
• Those who have a history of drug abuse within 1 year of screening or who have tested positive for urine drug tests

Sponsors & Collaborators

• Chong Kun Dang Pharmaceutical: lead

Study Sites (1)

Bumin Hospital(Seoul)

Seoul, Gangseo-gu, 07590, South Korea

Location

MeSH Terms

Conditions

Dyslipidemias

Condition Hierarchy (Ancestors)

Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 22, 2022
• First Posted: December 2, 2022
• Study Start: December 20, 2022
• Primary Completion: February 27, 2023
• Study Completion: June 7, 2023
• Last Updated: October 6, 2023

Record last verified: 2022-11

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)